Shanghai GoBroad Cancer Hospital, China Pharmaceutical University, is a tertiary-grade specialized research hospital under GoBroad Healthcare Group. Our Mission and Vision are Questing for Excellence in Diagnosis&Treatment Exploring Technological Innovation Create Possibilities in Life. We are dedicated to addressing complex diseases and advancing through clinically-driven research and innovation.

Shanghai GoBroad Cancer Hospital, China Pharmaceutical University, is located at No.170, Taipei East Road, Pudong New Area, Shanghai. With a total construction area of 70,000 square meters, the Phase I part of the project is currently operational, with 406 beds available. Phase II part of the project is under construction and is anticipated to commence operations in 2026. The combined capacity of Phases I and II is expected to accommodate approximately 700 beds.

Embodying the core philosophy of “The Needs of The Patient Come First” of GoBroad Healthcare Group, the hospital is deeply focused on oncology and tumor therapy, leading in cellular transplant therapy, cell targeted therapy for pancreatic cancer, lung cancer, digestive tract cancer, and more cancer. We have assembled a distinguished team of experts, both domestic and international, and offer a comprehensive range of services, including medical treatment, clinical research, integrated diagnostics, and a cancer multidisciplinary team. With the joint efforts of all of us, we are committed to making this hospital one of the best lung cancer hospitals and best breast cancer hospitals in the world. This establishment is a pivotal component of the GoBroad Innovative Medical Technology Platform. 

Rooted in the public service of clinical research, our hospital aims to transform the medical field through the advanced diagnosis and treatment of complex and severe cancers, clinical research, and the industrialization of biomedicine and medical devices. Our mission is to establish a research-driven hospital organization aligned with international standards, tailored to meet the innovative demands of China's biomedical industry. This approach is designed to enhance the capabilities of clinical research-focused medical institutions, boost the efficiency and quality of clinical research, and expedite the application of biomedical innovations.

To enhance medical efficiency and optimize patient experience, our hospital has introduced a direct payment system for both medical insurance and commercial insurance, while aligning the services with international healthcare standards, thereby providing patients with a dual-track, high-quality medical care experience.